Anebulo Pharmaceuticals, Inc. (ANEB) 10-Year Financial Performance & Capital Metrics

ANEB • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.Show more

Revenue $0
EBITDA -$8M -0.6%
Net Income -$8M -3.4%
EPS (Diluted) -0.25 +21.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -109.69% +3.6%
ROIC -1848.62% +89.3%
Debt/Equity -
Interest Coverage -24.14 +56.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 31.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM18.62%

ROCE

10Y Avg-66.31%

5Y Avg-78.33%

3Y Avg-108.12%

Latest-117.24%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	173.35K	3.61M	6.83M	11.78M	8.31M	9.22M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	23.35K	1.34M	3.87M	6.18M	4.76M	4.92M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	150K	2.27M	2.96M	5.6M	3.55M	4.3M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	-1.34K	0	0	0	0
Operating Income+	-173.35K	-3.61M	-6.83M	-11.78M	-8.31M	-9.22M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-19.85%	-0.89%	-0.72%	0.29%	-0.11%
EBITDA+	-173.35K	-30.24M	-6.83M	-11.73M	-8.05M	-8.1M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-173.45%	0.77%	-0.72%	0.31%	-0.01%
D&A (Non-Cash Add-back)	0	0	0	0	258.28K	0
EBIT	-173.35K	-30.24M	-6.83M	-11.73M	-8.05M	-8.1M
Net Interest Income+	-1.29K	-10.75K	7.33K	92.41K	97.79K	-124.1K
Interest Income	0	1.02K	7.33K	92.41K	249.02K	257.91K
Interest Expense	1.29K	11.77K	0	0	151.23K	382.01K
Other Income/Expense	-1.29K	-26.64M	5.55K	51.26K	107.05K	738.72K
Pretax Income+	-174.64K	-30.25M	-6.83M	-11.73M	-8.2M	-8.48M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-174.64K	-30.25M	-6.83M	-11.73M	-8.2M	-8.48M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-172.23%	0.77%	-0.72%	0.3%	-0.03%
Net Income (Continuing)	-174.64K	-30.25M	-6.83M	-11.73M	-8.2M	-8.48M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-1.30	-0.29	-0.47	-0.32	-0.25
EPS Growth %	-	-	0.78%	-0.62%	0.32%	0.22%
EPS (Basic)	-0.01	-1.30	-0.29	-0.47	-0.32	-0.25
Diluted Shares Outstanding	23.72M	23.34M	23.34M	25.07M	25.82M	33.82M
Basic Shares Outstanding	23.72M	23.34M	23.34M	25.07M	25.82M	33.82M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Current Assets+	3.03M	21.65M	15.58M	11.67M	3.51M	11.96M
Cash & Short-Term Investments	3.02M	19.99M	14.55M	11.25M	3.09M	11.63M
Cash Only	3.02M	19.99M	14.55M	11.25M	3.09M	11.63M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	3.5K	0	0	0	0	73.22K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0
Total Non-Current Assets+	0	0	0	0	565.12K	183.11K
Property, Plant & Equipment	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	565.12K	183.11K
Total Assets+	3.03M	21.65M	15.58M	11.67M	4.07M	12.15M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	6.15%	-0.28%	-0.25%	-0.65%	1.98%
Total Current Liabilities+	223.87K	241.63K	512.53K	1.07M	260.58K	224.18K
Accounts Payable	0	110.05K	380.83K	534.54K	156.43K	224.18K
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	201.29K	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	22.58K	0	0	0	0	-263.51K
Current Ratio	13.53x	89.61x	30.40x	10.92x	13.46x	53.36x
Quick Ratio	13.53x	89.61x	30.40x	10.92x	13.46x	53.36x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	263.51K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	263.51K
Total Liabilities	223.87K	241.63K	512.53K	1.07M	260.58K	487.69K
Total Debt+	201.29K	0	0	0	0	0
Net Debt	-2.82M	-19.99M	-14.55M	-11.25M	-3.09M	-11.63M
Debt / Equity	0.07x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-134.80x	-307.13x	-	-	-54.94x	-24.14x
Total Equity+	2.8M	21.41M	15.07M	10.6M	3.81M	11.66M
Equity Growth %	-	6.63%	-0.3%	-0.3%	-0.64%	2.06%
Book Value per Share	0.12	0.92	0.65	0.42	0.15	0.34
Total Shareholders' Equity	2.8M	21.41M	15.07M	10.6M	3.81M	11.66M
Common Stock	12K	23.34K	23.34K	25.63K	25.93K	41.09K
Retained Earnings	-183.14K	-38.64M	-45.47M	-57.2M	-65.4M	-73.89M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Cash from Operations+	-150.77K	-4.87M	-5.44M	-9.68M	-8.09M	-6.35M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-31.31%	-0.12%	-0.78%	0.16%	0.22%
Net Income	-174.64K	-30.25M	-6.83M	-11.73M	-8.2M	-8.48M
Depreciation & Amortization	0	0	0	0	0	382.01K
Stock-Based Compensation	0	199.95K	0	884.72K	0	1.45M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.29K	26.63M	480.66K	0	910.11K	0
Working Capital Changes	22.58K	-1.45M	907.78K	1.16M	-799.26K	306.24K
Change in Receivables	0	3.5K	0	0	0	-73.22K
Change in Inventory	0	-3.5K	0	0	0	0
Change in Payables	0	110.05K	270.78K	153.72K	-378.12K	67.75K
Cash from Investing+	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	3.18M	21.83M	0	6.38M	-62.35K	14.88M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	-821.63K	0	-264.68K	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-150.77K	-4.87M	-5.44M	-9.68M	-8.09M	-6.35M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-31.31%	-0.12%	-0.78%	0.16%	0.22%
FCF per Share	-0.01	-0.21	-0.23	-0.39	-0.31	-0.19
FCF Conversion (FCF/Net Income)	0.86x	0.16x	0.80x	0.83x	0.99x	0.75x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-6.23%	-249.85%	-37.42%	-91.42%	-113.81%	-109.69%
Return on Invested Capital (ROIC)	-	-385.25%	-526.92%	-	-17243.84%	-1848.62%
Debt / Equity	0.07x	-	-	-	-	-
Interest Coverage	-134.80x	-307.13x	-	-	-54.94x	-24.14x
FCF Conversion	0.86x	0.16x	0.80x	0.83x	0.99x	0.75x

Frequently Asked Questions

Growth & Financials

Anebulo Pharmaceuticals, Inc. (ANEB) grew revenue by 0.0% over the past year. Growth has been modest.

Anebulo Pharmaceuticals, Inc. (ANEB) reported a net loss of $8.4M for fiscal year 2025.

Dividend & Returns

Anebulo Pharmaceuticals, Inc. (ANEB) has a return on equity (ROE) of -109.7%. Negative ROE indicates the company is unprofitable.

Anebulo Pharmaceuticals, Inc. (ANEB) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener